Accueil > Actualité
Actualite financiere : Actualite bourse

Eli Lilly: purchase of Scorpion Therapeutics' PI3Kα program

(CercleFinance.com) - Eli Lilly and Company announces the acquisition of Scorpion Therapeutics' PI3Kα program, including the inhibitor STX-478, an oral treatment in Phase 1/2 clinical trials for breast cancer and other solid tumors.


STX-478 is distinguished by its ability to selectively target cancer cells, offering the potential for improved efficacy and tolerability.

The acquisition, valued at up to $2.5 billion, includes an upfront payment and payments linked to regulatory and commercial milestones.

Scorpion will spin off its other assets into a new entity, majority-owned by its current shareholders, with a minority stake from Lilly.

Completion of the transaction is subject to customary conditions.

Copyright (c) 2025 CercleFinance.com. All rights reserved.
 

societes

marches

tendances

 
Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.